Can-C™ Cataract Eye Drops

$39.00 or $37.05 / month

  • Reverses Cataracts*
  • Stimulates ocular healing and repair*
  • Reverses Oxidation and Glycation in the eye*
  • Original 1% N-acetylcarnosine lubricant formula*
  • Addresses root cause of dry eye*
  • Soothing natural anti-inflammatory*

Clinical studies show:

Initial results in only 3 months time!
Optimal Results within 6 – 12 months!

Based on applying 4 drops daily to each eye: 

  • (3 – 6 week supply) 1 – 2 boxes @ $39.00/box = 10% Savings!
  • (2 – 3 month supply) 3 – 4 boxes @ $35.00/box = 19% Savings!
  • (4 – 6 month supply) 6 – 8 boxes @ $31.50/box = 25% Savings!
  • Two (5ml) vials per box
  • Quantity discounts applied in your cart!
Subscribe & Save

Can-C™ is a proprietary form of N-acetylcarnosine, a highly specific intraocular released form of carnosine which acts as both a stabilizer and carrier for safe delivery into the aqueous humor of the eye. Once delivered into the aqueous humor this bio-identical molecule becomes highly active in the reduction of free radicals, oxidative stress and lens glycosylation.

Can-C™ Ingredients:

  • N-Acetyl-Carnosine (NAC) 1.0% (approved by IVP)
  • Glycerin (lubricant) 1.0%
  • Carboxymethylcellulose sodium (lubricant) 0.3%


Excipients:

  • Sterile Water (Ophthalmic Grade Isotonic Solution, pH 6.3 to 6.5)
  • Buffers: Potassium Bicarbonate and Boric Acid
  • Purified Benzyl Alcohol (Preservative) 0.3%

 

For bundles containing Can-C™ Cataract Eye Drops, please click here

Guaranteed Safe Checkout

Safe & Effective Ingredients

The healthy eye contains high levels of L-Carnosine. Interestingly, the eyes of those suffering from degenerative ocular diseases such as cataracts were found to be grossly deficient in this essential ocular antioxidant. Can-C™ replenishes the eye’s natural levels of this potent, natural antioxidant.

Clinically Proven Results

After 6 months, placebo-controlled clinical studies showed that eyes treated with the specific purified N-acetyl-carnosine:

  • 90% showed improvements in visual acuity
  • 89% had improvement of glare sensitivity.
  • 42% had an improvement of transmissivity of the lens.
  • These improvements lasted for the duration of treatment.

Enhancing the Eye's Restorative Properties

One of the most amazing features of the eye is its ability to repair itself and prevent infection after injury. Can-C™ drops support the healing process by keeping the eye well lubricated, delivering essential nutrients, enhancing DNA repair and reducing oxidative stress that could otherwise derail the natural healing process.

  • For Best Results
  • Why Can-C?
  • Research
  • FAQs
  • Reviews

A higher (loading) dose of Can-C™ Eye Drops is recommended in the first few months of use to quickly re-establish optimal N-Acetyl-Carnosine (NAC) levels in the eyes; two drops applied in the morning to each eye (4 drops total) and two drops in the evening to each eye (4 drops total). The quicker these levels can be elevated in your eyes the sooner you will begin to see visual improvements. This initial (loading dosing period) lasts anywhere from 3 to 6 months depending upon the severity of your eye condition.

Once you begin to see notable improvements in brightness and clarity you may be confident that you have effectively re-established optimal NAC levels in your eyes, but the improvements don’t stop there. The good news is that once the NAC levels have been re-established to optimal levels in the eyes it is very easy to keep them there at half the cost. After three to six months of consistent use, only half the recommended Can-C dose is needed to effectively maintain these new levels, and the vision improvements will continue.

While many report visual improvements in as little as three months’ time, generally the most dramatic improvements will be reached between six and twelve months of consistent use. Once optimal results have been achieved, the maintenance dose of only one to two drops daily will prevent the return of the Cataracts and continue to support and improve the health of your eyes.

The benefits of Can-C™ are long-lasting, however if the drops are discontinued, the same deficiency that allowed the ocular condition to form in the first place will likely return again. Fortunately, by simply using a minimal amount of the product consistently, the good results can be maintained at less than half the initial cost.

Can-C™ eye drops initial loading dose: two drops applied in the morning to each eye (4 drops total) and two drops in the evening to each eye (4 drops total).

Can-C™ eye drops maintenance dose (general eye health support and prevention): After 3 to 6 months of use you will only need to use 1-2 drops of Can-C™ in each eye daily, with a one week pause from use every two months. The product will last a very long time at this level of usage.

Advanced Program Protocol
Nac-C Plus™ Capsules dose: take 2 capsules daily Nac-C Plus™ Capsules. When used in conjunction with Can-C™ eye drops, Nac-C Plus capsules increase the length of time that Can-C™ eye drops stay active in the eye by inhibiting the breakdown of the L-carnosine that has been topically administered through the drops. This sustained effect significantly enhances free radical protection and decreases the oxidative environment within the eye, allowing for a faster healing response.

Independent clinical results are based on consistent daily use.

Can-C™ is a patented, proprietary form of N-acetylcarnosine (NAC)

Studies have shown that N-Acetyl-Carnosine (NAC) has a positive effect on lens clarity in people and dogs with age-related cataracts; it can help areas that were previously clouded to clear up and leads to improved vision, as well as helping to prevent the development of cataracts in the first place.(1)

Cataracts tend to result from oxidative stress, and L-Carnosine has been shown to have an antioxidant impact on a cataract-affected lens, enhancing DNA repair and helping to prevent DNA strand breaks caused by UV radiation.(2) However, regular L-Carnosine eye drops cannot penetrate the eye. When applied to the eye's surface, N-Acetyl-Carnosine moves past the cornea into a part of the eye that is closer to the cataract, where it is metabolized into L-Carnosine. Thus, using NAC eye drops may help reverse or even prevent cataract progression, improving vision and quality of life.(3)

L-Carnosine has been shown in clinical trials to be highly effective at protecting against and/or reversing cataracts and loss of vision.(4, 5) In fact, according to a Chinese trial on 96 patients aged 60 or older, Carnosine has a significant effect on primary senile cataracts, with a 100% effective rate. The impact rate for mature senile cataracts was 80%.(6)

The primary ingredient in Can-C™ is a proprietary form of N-Acetyl-Carnosine, a highly specific intraocular form of Carnosine which when applied topically to the eye, acts as both a stabilizer and time-release carrier for the di-peptide L-Carnosine, safely delivering it into the aqueous humour of the eye. Here, in the fluid area surrounding the lens, L-Carnosine becomes most active in its ability to act as a natural and highly effective free radical scavenger, enhancing DNA repair and helping to prevent DNA strand breaks caused by UV radiation.(7)

L-Carnosine's most important cataract-inhibiting activity may be its capacity to compete with proteins for binding sites on sugar molecules, thereby preventing the production of advanced glycated end products (protein crosslinks).(8-11)

Dr. Mark Babizhayev, inventor of Can-C, demonstrated in research studies that using non-approved n-acetyl carnosine formulations will not help treat senile cataract due to lack of anti-cataract and antioxidant properties. Look for the approved Can-C hologram on the box of any Can-C eye drop product prior to applying to the eyes.

The biological activity and therapeutic value of “carnosines” varies greatly depending on their source. For example, extractions from meat muscle components have minimal biological and antioxidant action due to heavy metal salts, proteins, and other impurities.

Carnosine is difficult to purify chromatographically because it chelates divalent metal ions extensively making it difficult to retain its biological and antioxidant activities. Only the patented Can-C™ N-acetylcarnosine eye drops should be applied to the eyes.

Innovative Vision Products (IVP), in collaboration with their Japanese partner, spent years researching to identify a specific purity level of N-acetyl-carnosine (NAC) that that would ensure both safety and optimal results. They have discovered, developed and patented a highly purified form of n-acetyl carnosine, which has excellent biological activity and has been proven effective in controlled human lens studies.

Note: After 6 months optimal N-Acetyl-Carnosine levels have been re-established in the eyes at which time a reduction to half the recommended amount provides ongoing support for continued vision improvement at half the cost!

  1. "Revival of the Lens Transparency with N-Acetylcarnosine", Babizhayev et. al., Current Drug Therapy, Volume 1, Issue 1, 2006, pg 91-116, https://www.eurekaselect.com/55159/article/revival-lens-transparency-n-acetylcarnosine
  2. Lou M F. Thiol regulation in the lens. J Ocul Pharmacol Ther 2000 Apr; 16(2):137-48. https://pubmed.ncbi.nlm.nih.gov/10803424/
  3. "N-Acetylcarnosine (NAC) Drops for Age-Related Cataract" Dubois & Bastawrous, https://pubmed.ncbi.nlm.nih.gov/28245346/
  4. Quinn P J, et al. Carnosine: its properties, functions and potential therapeutic applications. Mol Aspects Med 1992; 13(5):379-444. https://pubmed.ncbi.nlm.nih.gov/9765790/
  5. Specht S, et al. Continuing damage to rat retinal DNA during darkness following light exposure. Photochem Photobiol 2000; 71(5):559-66. https://pubmed.ncbi.nlm.nih.gov/10818786/
  6. Wang AM, et al. Use of carnosine as a natural anti-senescence drug for human beings. Department of Biochemistry and Department of Neurobiology, Harbin Medical University, China 1999. https://pubmed.ncbi.nlm.nih.gov/10951108/
  7. Lou M F. Thiol regulation in the lens. J Ocul Pharmacol Ther 2000 Apr; 16(2):137-48. https://pubmed.ncbi.nlm.nih.gov/10803424/
  8. Ghodsi R, Kheirouri S. Carnosine and advanced glycation end products: a systematic review. Amino Acids. 2018 Sep;50(9):1177-1186. doi: 10.1007/s00726-018-2592-9. Epub 2018 Jun 1. PMID: 29858687. https://pubmed.ncbi.nlm.nih.gov/29858687/
  9. Michael A. Freund, Bingcan Chen, Eric A. Decker. The Inhibition of Advanced Glycation End Products by Carnosine and Other Natural Dipeptides to Reduce Diabetic and Age-Related Complications. 2018 July 27. doi: 10.1111/1541-4337.12376 https://onlinelibrary.wiley.com/doi/full/10.1111/1541-4337.12376
  10. Abdelkader H, Longman M, Alany RG, et al. On the Anticataractogenic Effects of L-Carnosine: Is It Best Described as an Antioxidant, Metal-Chelating Agent or Glycation Inhibitor? Oxid Med Cell Longev. 2016;2016:3240261. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086400/
  11. Liang J N, Chylack LT, Jr. Spectroscopic study on the effects of nonenzymatic glycation in human alpha-crystallin. Invest Ophthalmol Vis Sci. 1987;28(5):790-4. https://pubmed.ncbi.nlm.nih.gov/3570690/

CLINICAL STUDY

In study 90.0% of the eyes treated with N-acetylcarnosine, 1% sol (NAC) showed a gradual improvement in b/c VA to 7-100%

Study: N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts.
Publication: PMID: 11390029 DOI: 10.1016/s0196-9781(01)00407-7
Date published: January 28, 2022
Authors: M A Babizhayev, A I Deyev, V N Yermakova, Y A Semiletov, N G Davydova, N I Kurysheva, A V Zhukotskii, I M Goldman
Summary: A study was designed to document and quantify the changes in lens clarity over 6 and 24 months in 2 groups of 49 volunteers (76 eyes) with an average age of 65.3 +/- 7.0 enrolled at the time of diagnosis of senile cataracts of minimal to advanced opacification. The patients received N-acetylcarnosine, 1% sol (NAC) (26 patients, 41 eyes = Group II), placebo composition (13 patients, 21 eyes) topically (two drops, twice daily) to the conjunctival sac, or were untreated (10 patients, 14 eyes); the placebo and untreated groups were combined into the control (reference) Group I. Patients were evaluated upon entry, at 2-month (Trial 1) and 6-month (Trial 2)-intervals for best corrected visual acuity (b/c VA), by ophthalmoscopy and the original techniques of glare test (for Trial 1), stereocinematographic slit-image and retro-illumination photography with subsequent scanning of the lens. The computerized interactive digital analysis of obtained images displayed the light scattering/absorbing centers of the lens into 2-D and 3-D scales. The intra-reader reproducibility of measuring techniques for cataractous changes was good, with the overall average of correlation coefficients for the image analytical data 0.830 and the glare test readings 0.998. Compared with the baseline examination, over 6 months 41.5% of the eyes treated with NAC presented a significant improvement of the gross transmissivity degree of lenses computed from the images, 90.0% of the eyes showed a gradual improvement in b/c VA to 7-100% and 88.9% of the eyes ranged a 27-100% improvement in glare sensitivity. Topographic studies demonstrated less density and corresponding areas of opacification in posterior subcapsular and cortical morphological regions of the lens consistent with VA up to 0.3. The total study period over 24 months revealed that the beneficial effect of NAC is sustainable. No cases resulted in a worsening of VA and image analytical readings of lenses in the NAC-treated group of patients. In most of the patients drug tolerance was good. Group I of patients demonstrated the variability in the densitometric readings of the lens cloudings, negative advance in glare sensitivity over 6 months and gradual deterioration of VA and gross transmissivity of lenses over 24 months compared with the baseline and 6-month follow-up examinations. Statistical analysis revealed the significant differences over 6 and 24 months in cumulative positive changes of overall characteristics of cataracts in the NAC-treated Group II from the control Group I. The N-acetylated form of natural dipeptide L-carnosine appears to be suitable and physiologically acceptable for nonsurgical treatment for senile cataracts.

CLINICAL STUDY

In clinical test NAC-treated eyes had statistically significant difference in VA, glare sensitivity compared to control at 4-months

Study: Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops.
Publication: PMID: 15588519 DOI: 10.1089/rej.2004.7.186
Date published: January 28, 2006
Authors: Mark A Babizhayev
Summary: The purpose of this study was to examine using the original halometer glare test of the type of visual impairment mediated by the increased glare sensitivity (halos) and associated with poorer visual function in both the better and worse eyes of older adult drivers and older drivers with cataract. The clinically validated original formula of 1% N-acetylcarnosine (NAC) lubricant eye drops were applied topically to the eyes of older drivers to reduce glare disability and improve distance acuities for driving. This was a randomized, double-blind, placebo-controlled study. The examined subjects consisted of 65 older adults, with cataract in one or both eyes, and 72 adult drivers who did not have cataract in either eye. In the control group, comparison with baseline values showed some variability of data in gradual worsening of glare sensitivity at red and green targets and minimal VA changes over 4 months. In the NAC-treated group, 4-month follow-up generally showed an improvement in VA and a significant improvement in glare sensitivity at red and green targets was documented in worse and better eyes using a critical cut point halometer score for driving. The NAC-treated eyes had statistically significant difference in VA, glare sensitivity compared with the control group ( p < 0.001) at 4-month timepoint of treatment, as supported by the overall t-test results of the ratio of the follow-up data to the baseline values. Tolerability of NAC eyedrops was good in almost all patients, with no reports of ocular or systemic adverse effects. The results of this study provide a substantial basis for further evaluation of NAC in the treatment and prevention of vision impairment in the older population of drivers for legal driving. The developed ophthalmic drug NAC formula showed potential for the non-surgical treatment of age-related cataracts.

What if I just want to improve the health of my eyes?
The dose for general eye health support and prevention is half the recommended dose for cataract reversal. Apply only two drops daily to each eye.
When will I begin to notice initial changes or improvements?
Typically, you will begin to see signs of initial results after the first 90 days of the recommended daily dosage. Results are more significant after 4 to 5 months and even more, dramatic results are achieved after 6 to 8 months. Because cataracts, and most other age-related eye disorders, are caused by low anti-oxidant and high free-radical activity, the regular and consistent use of Can-C™ has been shown to be an excellent, non-invasive option, for the treatment and even reversal of cataracts and other eye conditions.
Are there any vitamins or supplements that conflict with Can-C?
Yes, there are two; Lutein and Zeaxanthin. While in most cases taking vitamin supplements in no way conflict with the good effects of Can-C™ eye drops, Lutein and Zeaxanthin in the supplement form can be too much of a good thing as their pathway of action is the same as CanC. Please note that Can-C with N-acetyl carnosine is far more direct in its ability to address the problem of cataract and if combined with Lutein and Zeaxanthin can create a sort of imbalance that is not optimal. Lutein and Zeaxanthin can still be consumed in foods as it is only in supplement form that they are contraindicated. Once optimal results have been achieved and the lower maintenance dose of 1 drop daily is being used, Lutein and/or Zeaxanthin supplements may be re-introduced as part of the overall ocular health management effort. All other antioxidants and supplements can be continued and may certainly be of benefit to the end result.
Click here for additional FAQ's
Hello, I have been using your Can-C eye drops for 6 months to address a very newly diagnosed cataract. I haven't returned to the eye doctor yet but the interesting improvement is that my irritating floaters appear to have completely vanished. I almost had forgotten about them entirely because they were no longer in my vision and then one day I realized that they were not there! This is truly amazing and I am now very anxious to learn what my doctor has to say about my cataract. I truly want to thank you!* Carol B. Huntersville N.C.
Good news to report! It is too good for words. I have been using the eye drops for a month for cataracts in both of my eyes. The first thing I noticed was that lights seem brighter and have noticed that print is easier to read. I am near-sighted also, so being able to see numbers more clearly on a hymn board across the room is very exciting! I am hoping for more clarity as I continue to use the drops. This is too good to be true but it really is!* BB London
Dear Leslie, I am writing to let you know that I have been using Can-C to address a cataract in my right eye for a little more than 6 months and want to check with you as I am now ready to start with the maintenance dose of 1 drop a day. Earlier this year I had been noticing growing cloudiness in my vision and when I went to my eye doctor about 7 months ago March of 2007 I was diagnosed with a cataract in my right eye. I immediately went online and began researching and found Wise Choice Medicine and began using your Can-C eye drops daily as recommended. I didn't see much improvement at first but now I am amazed as my vision has progressively become clearer and clearer and today it is crystal clear in that eye. In addition to being overjoyed with the amazing improvement in my eyesight, it is fantastic to have invested in something that actually does what it says it will. I am sure that I will be a lifetime customer as you guys have an amazing product and I for one certainly want to thank you for it.* Sol H. New Jersey
Click here for additional Reviews

Bundles containing Can-C™ Cataract Eye Drops

Welcome to the shiny new WiseChoiceMedicine.com!

Finding the best vision support solutions has never been easier thanks to side-by-side program comparisons and access to the extensive clinical research supporting our products.

For any questions please contact our helpful and knowledgable support team at 1-800.861.4936